WebApr 12, 2024 · Examples of forward-looking statements include, among others, that the Decipher Prostate test may have a real-world impact on patient care and outcomes. … WebJul 20, 2024 · Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating...
Impact of Decipher Biopsy testing on clinical outcomes in …
WebOct 13, 2024 · In a new study, a genomic test appeared to be better at finding aggressive prostate cancer than conventional tests. The genomic test, called Decipher, looks at the activity of 22 genes and has been … WebDecipher Prostate was developed from a large cohort of metastatic and non-metastatic prostate cancer patients treated at the Mayo Clinic. The whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a … Decipher Prostate Genomic Classifier Post-Biopsy. Awasthi S, et al. Genomic … Decipher Prostate is covered by Medicare, Medicare Advantage and select private … black screen to white screen
WebJan 4, 2015 · Myriad’s Prolaris test received draft language for reimbursement for approximately 50% of prostate cancer patients defined as low and very low risk, while the Decipher test received draft... WebApr 12, 2024 · Examples of forward-looking statements include, among others, that the Decipher Prostate test may have a real-world impact on patient care and outcomes. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed … WebMay 1, 2024 · I pulled the results just to make sure I got this right and it indicates he is low risk. Stating: Independent of clinical risk factors, your five year Decipher genomic risk of metastasis after radical prostatectomy is 0.6%. Your Decipher risk is 0.1 times the average patient with adverse pathology. garrinetteteague yahoo.com